UroGen Pharma Ltd is a biotech company based in Princeton, NJ, dedicated to developing and commercializing innovative solutions for urothelial and specialty cancers. Their groundbreaking therapies and clinical pipeline aim to revolutionize the treatment of these cancers by maximizing the potential benefit of local delivery through their novel RTGel technology, offering transformative, nonsurgical approaches to patients.
UroGen is at the forefront of a transformative shift in urothelial and specialty cancer treatment, moving away from invasive surgeries towards nonsurgical means. Their first commercial product, JELMYTO mitomycin for pyelocalyceal solution, is the first and only FDA-approved nonsurgical treatment of its kind, utilizing their RTGel technology. With a focus on fundamentally changing the treatment paradigm, UroGen is committed to providing noninvasive therapeutic options for some of the most devastating cancers.
Generated from the website